Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- MNOV
- Price
- 1.60
- Stock movement up
- +0.12 (8.11%)
- Company name
- MediciNova Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 78.75M
- Ent value
- 51.96M
- Price/Sales
- 192.24
- Price/Book
- 1.89
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -4.75%
- 1 year return (CAGR)
- -14.44%
- 3 year return (CAGR)
- -13.24%
- 5 year return (CAGR)
- -24.68%
- 10 year return (CAGR)
- -9.13%
Last updated: 2026-03-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MNOV does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 192.24 |
| Price to Book | 1.89 |
| EV to Sales | 126.85 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 49.22M |
| EPS (TTM) | -0.24 |
| FCF per share (TTM) | -0.20 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 409.66K |
| Gross profit (TTM) | 25.87K |
| Operating income (TTM) | -13.28M |
| Net income (TTM) | -12.00M |
| EPS (TTM) | -0.24 |
| EPS (1y forward) | -0.40 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 6.32% |
| Operating margin (TTM) | -3242.47% |
| Profit margin (TTM) | -2928.78% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 30.81M |
| Net receivables | 0.00 |
| Total current assets | 30.99M |
| Goodwill | 9.60M |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 45.60M |
| Accounts payable | 625.00K |
| Short/Current long term debt | 194.33K |
| Total current liabilities | 3.80M |
| Total liabilities | 4.02M |
| Shareholder's equity | 41.59M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -9.81M |
| Capital expenditures (TTM) | 5.81K |
| Free cash flow (TTM) | -9.82M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -28.85% |
| Return on Assets | -26.31% |
| Return on Invested Capital | -28.72% |
| Cash Return on Invested Capital | -23.49% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.56 |
| Daily high | 1.63 |
| Daily low | 1.55 |
| Daily Volume | 59K |
| All-time high | 14.28 |
| 1y analyst estimate | 10.00 |
| Beta | 0.60 |
| EPS (TTM) | -0.24 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 19 Feb 2026 |
Downside potential
Loading...
Downside potential data
| MNOV | S&P500 | |
| Current price drop from All-time high | -88.80% | -1.82% |
| Highest price drop | -92.09% | -56.47% |
| Date of highest drop | 12 Aug 2024 | 9 Mar 2009 |
| Avg drop from high | -68.75% | -10.84% |
| Avg time to new high | 780 days | 12 days |
| Max time to new high | 4667 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
78.75M
Marketcap category
Small-cap
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Employees
13
Website
Investor relations
-
SEC filings
CEO
Yuichi Iwaki
Country
USA
City
La Jolla
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page